REGN Regeneron Pharmaceuticals Inc.

Top 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation’s Oldest and Most Prestigious Science and Math Competition

Top 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation’s Oldest and Most Prestigious Science and Math Competition

Nation’s Most Innovative Teens will Showcase Research with Prizes of Over $1.8 million

TARRYTOWN, N.Y. and WASHINGTON, D.C., Jan. 24, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: REGN) and (the Society) today announced the top 40 finalists in this year’s , the nation’s oldest and most prestigious science and math competition for high school seniors. The competition, now in its 82nd year, celebrates and rewards young scientists focused on a wide range of scientific topics from the space race to the AIDS epidemic to climate change. Many past winners continue to pursue innovation for the good of society and the planet, with program alumni receiving some of the world’s most coveted science and math honors, including 13 Nobel Prizes and 22 MacArthur Foundation Fellowships, as well as becoming the founders of many important science-based companies, such as Regeneron.

The 2023 finalists’ research projects showcase their breadth of knowledge, their commitment to addressing issues important to modern society, and their passion for STEM. Multiple students chose to explore research topics on climate change; for instance, one studied the environmental potential of human-made materials such as cement to help reduce emissions, and another evaluated the correlation between air pollution and COVID-19 cases. Some students invented health monitoring devices, like a color-changing sensor to help detect the presence of illicit drugs in drinks; others explored topics related to space, including a new method to test for the existence of large populations of black holes. Other finalists dove into social and political issues, including an examination of media coverage about violent crimes to understand its impact on societal perceptions, and an evaluation of linguistic features in writing to predict suicide risk.

“Congratulations to an exceptional group of Regeneron Science Talent Search 2023 finalists,” said George D. Yancopoulos, M.D., Ph.D., Co-founder, President and Chief Scientific Officer of Regeneron, and a 1976 Science Talent Search finalist and top winner. “Inspiring and equipping the brightest minds to take on the world’s most pressing issues is one of the most important ways we can ensure the scientific advancements necessary to better our society. We know the future is bright for these young scientists and are excited to see the positive impact they will make.”

The finalists were chosen based on their projects’ scientific rigor and their potential to become world-changing scientific leaders. Finalists were selected by a national jury of professional scientists from a pool of 300 scholars, who were earlier this month. The scholars were chosen from a pool of over 1,900 highly-qualified entrants, all of whom completed an original research project and extensive application process.

“We are thrilled to welcome this inspiring and highly talented class of Regeneron Science Talent Search finalists,” said Maya Ajmera, President and CEO, Society for Science and Executive Publisher, Science News. “I am certain these extraordinary students will be following in the footsteps of our many accomplished alumni who are the forefront of breakthrough discoveries. The 2023 finalists will be using their leadership, intellect, creativity and STEM skills to solve our world’s most intractable challenges.”

Finalists will participate in a week-long competition in March 2023, during which they will undergo a rigorous judging process that goes beyond their own research to encompass other scientific disciplines and compete for more than $1.8 million in awards. They will also have an opportunity to interact with leading scientists and share their research during a virtual “Public Day” event on March 12. The top 10 Regeneron Science Talent Search 2023 winners will be announced during an awards ceremony on March 14, streamed live from Washington, D.C.

In total, more than $3 million in awards will be distributed throughout the Regeneron Science Talent Search. The finalists are each awarded at least $25,000, and the top 10 awards range from $40,000 to $250,000. Finalists may use their award prize money solely for educational purposes and can choose for those funds to be released directly to their college or university. The top 300 scholars, each of whom receive $2,000, may use their awards as they see fit; each of their schools are also awarded $2,000 to support math and science programs, a critical investment toward their future in STEM, and our country’s future as a hub of innovation and progress.

Regeneron Science Talent Search 2023 Fast Facts

  • The Regeneron Science Talent Search 2023 finalists represent 34 schools across 14 states. They are competing for more than $1.8 million, with a top prize of $250,000.

  • Forty finalists were selected from 300 scholars and 1,949 entrants based on the originality and creativity of their scientific research, as well as their achievement and leadership both inside and outside of the classroom.



  • Finalist projects cover disciplines of science including animal sciences, behavioral and social sciences, biochemistry, cellular and molecular biology, chemistry, computational biology and bioinformatics, computer science, engineering, environmental science, genomics, mathematics, medicine and health, neuroscience, physics, plant science, and space science.



  • For a list of this year’s finalists, visit

About the Regeneron Science Talent Search

The Regeneron Science Talent Search, a program of Society for Science since 1942, is the nation’s oldest and most prestigious science and math competition for high school seniors. Each year, nearly 2,000 student entrants submit original research in critically important scientific fields of study and are judged by leading experts in their fields. Unique among high school competitions in the U.S. and around the world, the Regeneron Science Talent Search focuses on identifying, inspiring and engaging the nation’s most promising young scientists who are creating the ideas that could solve society’s most urgent challenges.

In 2017,  became only the third sponsor of the Science Talent Search to help reward and celebrate the best and brightest young minds and encourage them to pursue careers in STEM as a way to positively impact the world. Through its 10-year, $100 million commitment, Regeneron nearly doubled the overall award distribution to $3.1 million annually, increasing the top award to $250,000 and doubling the awards for the top 300 scholars to $2,000 and their schools to $2,000 for each enrolled scholar to inspire more young people to engage in science.

Learn more at .

About Society for Science

Society for Science is a champion for science, dedicated to promoting the understanding and appreciation of science and the vital role it plays in human advancement. Established in 1921, Society for Science is best known for its award-winning journalism through Science News and Science News Explores, its world-class science research competitions for students, including the Regeneron Science Talent Search, the Regeneron International Science and Engineering Fair and the Thermo Fisher Scientific Junior Innovators Challenge, and its outreach and equity programming that seeks to ensure that all students have an opportunity to pursue a career in STEM. A 501(c)(3) membership organization, Society for Science is committed to inform, educate and inspire. Learn more at  and follow us on , ,  and Snapchat (Society4Science).

About Regeneron

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, nearly all of which were homegrown in our laboratories. Our two most senior leaders, Leonard Schleifer, M.D., Ph.D., and George Yancopoulos, M.D., Ph.D., credit their experiences at the Science Talent Search for putting them on a path to start the company and ultimately, along with their team, invent important, life-changing medicines. Our medicines and pipeline are designed to help people with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases.

Regeneron believes that operating as a good corporate citizen is crucial to delivering on our mission. We approach corporate responsibility with three goals in mind: to improve the lives of people with serious disease, to foster a culture of integrity and excellence and to build sustainable communities. Regeneron is proud to be included on the Dow Jones Sustainability World Index and the Civic 50 list of the most “community-minded” companies in the U.S. Throughout the year, Regeneron empowers and supports employees to give back through our volunteering, pro-bono and matching gift programs. Our most significant philanthropic commitments are in the area of science education, including the  and .

For additional information about the company, please visit or follow @Regeneron on Twitter.

Media Contacts

Joseph Brown, Regeneron

386-283-1323,

Gayle Kansagor, Society for Science

703-489-1131,



EN
24/01/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Regeneron Pharmaceuticals Inc.

 PRESS RELEASE

Garetosmab Biologics License Application Accepted for FDA Priority Rev...

Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP) FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability  If approved, garetosmab would be the first and only available treatment shown to reduce the number and volume of new heterotopic bone lesions in adults with FOP TARRYTOWN, N.Y., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) toda...

Regeneron Pharmaceuticals Inc: 2 directors

Two Directors at Regeneron Pharmaceuticals Inc sold/sold after exercising options 2,136 shares at between 778.516USD and 778.526USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary tr...

 PRESS RELEASE

Regeneron Announces Investor Conference Presentations

Regeneron Announces Investor Conference Presentations TARRYTOWN, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: TD Cowen 46th Annual Health Care Conference at 9:10 a.m. ET on Wednesday, March 4, 2026Leerink Partners 2026 Global Healthcare Conference at 10:40 a.m. ET on Wednesday, March 11, 2026 The sessions may be accessed from the "Investors & Media" page of Regeneron's website at . Replays and transcripts of the webcasts will be archived on the Company's website for at least 30 days. About Regen...

 PRESS RELEASE

Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AA...

Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy 36 abstracts to be presented across Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for cat and birch allergies New Dupixent® (dupilumab) data highlight its clinical and real-world impact across dermatological, respiratory and gastrointestinal diseases, including analyses of food allergy sensitization in children with atopic dermatitis TARRYTOWN, N.Y., Feb. 10, 2026 (GLOBE NEWSWIR...

 PRESS RELEASE

EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2...

EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated with monthly dosing TARRYTOWN, N.Y., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual Angiogenes...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch